ClinicalTrials.gg

Program

vonicog alfa

Also written as “Vonicog Alfa”, “Vonicog alfa” and “VONVENDI”.

Its studies are mostly in von Willebrand Diseases, led by Takeda.

Furthest: phase 3, since Aug 4, 20116 company-led studies, 2 open or runningNext primary completion: Nov 25, 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Takeda62 open or runningphase 3since Aug 4, 2011Aug 4, 2011Nov 25, 2027phase 3 · NCT07129343

Also a collaborator on its studies: takeda-development-center-americas-inc and baxalta-innovations-gmbh-now-part-of-shire.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Aug 4, 2011First study: phase 3 study in von Willebrand DiseasesFirst studyNCT01410227 · 49 enrolled · United States, Australia, Austria and more
  2. Oct 27, 2014Phase 3 study in von Willebrand DiseasesNCT02283268 · 24 enrolled · United States, Australia, Austria and more
  3. Oct 12, 2016Phase 3 study in von Willebrand DiseasesNCT02932618 · 47 enrolled · United States, Austria, Belgium and more
  4. Nov 22, 2016Phase 3 study in von Willebrand DiseasesNCT02973087 · 29 enrolled · United States, Canada, France and more
  5. Oct 14, 2022Phase 3 study in von Willebrand DiseasesNCT05582993 · 24 planned · United States, France, Ireland and more
  6. Aug 12, 2025Phase 3 study in von Willebrand DiseasesNCT07129343 · 20 planned · China

Ahead

  1. Nov 25, 2027Primary completion: phase 3 study in von Willebrand DiseasesNCT07129343
  2. Apr 11, 2030Primary completion: phase 3 study in von Willebrand DiseasesNCT05582993

TargetBeta

VWF →read by rule
“von Willebrand factor exogenous protein”ChEMBL 37, by rule

Studies

All 6 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07129343von Willebrand Diseases · China3RecruitingNov 25, 202720
NCT05582993von Willebrand Diseases · United States, France, Ireland and more3RecruitingApr 11, 203024
NCT02973087von Willebrand Diseases · United States, Canada, France and more3CompletedJul 6, 202029
NCT02932618von Willebrand Diseases · United States, Austria, Belgium and more3CompletedApr 17, 202647
NCT02283268von Willebrand Diseases · United States, Australia, Austria and more3CompletedJul 6, 201624
NCT01410227von Willebrand Diseases · United States, Australia, Austria and more3CompletedFeb 1, 201449

How it is read

Names in the registry

  • “Vonicog Alfa”, 1 entry
  • “Vonicog alfa”, 1 entry
  • “VONVENDI”, 1 entry
  • “von Willebrand factor (Recombinant)”, 1 entry
  • “Recombinant von Willebrand factor (rVWF)”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.